
    
      Initially, the safety, side effects and recommended phase 2 dose of oral Karenitecin in
      patients with advanced solid tumors will be determined.

      When the recommended phase 2 dose has been determined, the specified dose will be used to
      determine if Karenitecin is effective in the treatment of patients with relapsed or
      refractory non-small cell lung cancer.
    
  